Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BreAK CRC phase I/IIa trial of STC-1010 in advanced colorectal cancer
2024-512011-45-00Phase 2Authorised
- Sponsor
- Brenus Pharma
- Start
- Jun 2025
- Modality
- Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 3
01
Overview
Phase 2, open-label trial of STC-1010 in colorectal cancer (CRC) (3 arms), sponsored by Brenus Pharma. Primary endpoints: Phase I safety and tolerability and Phase IIa 12-month progression-free survival rate. Planned start Jun 2025; status: authorised.
02
Drugs
STC-1010
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2024-512011-45-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512011-45-00.